The novel target products were synthesized in the formation of a triazine ring from berberine, magnolol, and metformin catalyzed by sodium methylate. The structures of products 1-3 were firstly confirmed by extensive spectroscopic analyses and single-crystal X-ray diffraction. The crystal structures of the target product 2 and the intermediate product 7b were reported for the first time. All target products were evaluated for their anti-inflammatory and antidiabetic activities against INS-1 and RAW264.1 cells in vitro and all products showed excellent anti-inflammatory effects and anti-insulin resistance effects. Our studies indicated that new compounds 1-3 were found to be active against inflammation and insulin resistance.
Introduction
Berberine is an isoquinoline alkaloid originally isolated from the Chinese herb Coptis chinensis (Huang lian) and is one of the main components of R. Coptidis [1] . Magnolol is a 4-allyl-2-(5-allyl-2-hydroxy-phenyl) phenol, and is present in considerable quantities in the bark of the Houpu magnolia (Magnolia officinalis) [2] . Previous data showed that berberine and magnolol were extensively employed in traditional Chinese medicine for the treatment of diabetes, cancers, inflammations, and hyperlipoidemia [3] [4] [5] [6] [7] [8] .
Metformin has been widely applied in clinics since the 1950s [9] . Over the past decades, metformin has been recommended as a first-line antidiabetic therapy for the treatment of type 2 diabetes mellitus (T2DM) based on the official guidelines of the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the American Association of Clinical Endocrinologists (AACE) [10, 11] . Moreover, it takes part in the regulation of reduced insulin resistance and blood glucose concentration [12] .
According to a review of recent advances in structural modifications of metformin, a variety of metformin derivatives have been successfully synthesized. In 2005, Viollet synthesized new 3d and 4f complex compounds with metformin that were utilized for the treatment of diabetic patients with non-insulin-dependent diabetes mellitus [13] . Liu synthesized seven derivatives of 2-amino-4-dimethylamino-1,3,5-triazine and obtained pure target compounds from silica gel column chromatography in the same year [14] . Additionally, berberine and magnolol derivatives have 
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The synthetic strategy for preparing compounds 1 and 2 is outlined in Scheme 1, and the strategy for compound 3 is outlined in Scheme 2. Briefly, it is based on the alkylation of phenolic OH groups of magnolol (5) and berberrubine (9) with methyl bromoacetate and a subsequent ring closure reaction with metformin (a biguanide) in alkaline medium to afford the final 1,3,5-triazine derivatives (1, 2 and 3). During the development of compounds 1 and 2, we started by alkylation; reacting magnolol (5) with methyl bromoacetate (6) . The reaction proceeded smoothly under mild conditions. Two phenolic OH groups of magnolol (5) engaged in alkylation with the bromine group of methyl 
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Then, we studied the reaction under various conditions of alkylation reactions (Tables S5 and S6 ). Our studies were initiated using dichloromethane (DCM) with Na 2 CO 3 for compound 7, methanol (MeOH) for compound 10, and methanol (MeOH) with 8 mL of a sodium methylate (NaOCH 3 ) solution (5 mol/L) for compounds 1-3 at room temperature (25 • C). After screening the reaction conditions, using Na 2 CO 3 as the base catalyst and methanol as the solvent reacted at 65 • C for 6 h was determined to be optimal for the synthesis of product 7 (Table S5 , entry 11). DCM as the solvent reacted at 45 • C for 8 h was determined to be optimal for the synthesis of product 10 in 80% yield (Table S6 , entry 9).
Using these optimized conditions (Table S5, entry 11 and Table S6 , entry 9), we examined the substrate scope of the cyclization reaction (Table S7 ). The best conditions for the reaction of compounds 1-3 were determined to be CH 3 ONa as the base catalyst and methanol as the solvent, reacted at 65 • C for 12 h (Table S7 , entry 12). Then, we studied the reaction under various conditions of alkylation reactions (Tables S5 and S6 ). Our studies were initiated using dichloromethane (DCM) with Na2CO3 for compound 7, methanol (MeOH) for compound 10, and methanol (MeOH) with 8 mL of a sodium methylate (NaOCH3) solution (5 mol/L) for compounds 1-3 at room temperature (25 °C). After screening the reaction conditions, using Na2CO3 as the base catalyst and methanol as the solvent reacted at 65 °C for 6 h was determined to be optimal for the synthesis of product 7 (Table S5 , entry 11). DCM as the solvent reacted at 45 °C for 8 h was determined to be optimal for the synthesis of product 10 in 80% yield (Table S6 , entry 9).
Characterization of Compounds
Using these optimized conditions (Table S5, entry 11 and Table S6 , entry 9), we examined the substrate scope of the cyclization reaction (Table S7 ). The best conditions for the reaction of compounds 1-3 were determined to be CH3ONa as the base catalyst and methanol as the solvent, reacted at 65 °C for 12 h (Table S7 , entry 12). Compound 2 has a completely symmetric structure. A detailed comparison of the 13 C-NMR data (Table S10 ) and 2D-NMR spectra of 2 and 1 revealed that the structure of 2 was very similar to that of 1. The only difference was the replacement of the carbonyl group in 1 by an additional moiety of 4 in 2, as confirmed by the HMBC of H-10/C-11, H-14/C-13, and H-15/C-13.
The molecular formula of compound 3, C25H25N6O4 + , was established by HRESIMS (m/z = 473.1936 M + , calcd = 473.1937) and 13 C-NMR data, requiring 13 degrees of unsaturation. The FT-IR spectrum of compound 1 ( Figure S23 ) suggested the presence of a primary amine group (1674.87 cm −1 ) and benzene rings (1600.63 cm −1 , 1553.38 cm −1 , and 1491.67 cm −1 ). The 1 H-NMR data of 3 displayed signals for two methyl groups at δH = 2.179 (d) and a methoxyl group at δH = 3. Compound 2 has a completely symmetric structure. A detailed comparison of the 13 C-NMR data (Table S10 ) and 2D-NMR spectra of 2 and 1 revealed that the structure of 2 was very similar to that of 1. The only difference was the replacement of the carbonyl group in 1 by an additional moiety of 4 in 2, as confirmed by the HMBC of H-10/C-11, H-14/C-13, and H-15/C-13. Compound 2 has a completely symmetric structure. A detailed comparison of the 13 C-NMR data (Table S10 ) and 2D-NMR spectra of 2 and 1 revealed that the structure of 2 was very similar to that of 1. The only difference was the replacement of the carbonyl group in 1 by an additional moiety of 4 in 2, as confirmed by the HMBC of H-10/C-11, H-14/C-13, and H-15/C-13. 
Biological Evaluation
In order to evaluate the anti-inflammatory activities and antidiabetic activities of the synthesized compounds 1-3, we chose RAW264.1 cells (mice inflammatory cells) and INS-1 cells (mouse insulinoma cells). Cell viability was measured by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. RAW264.7 cell cultures were pretreated with a series of compounds 1-3 or vehicle to evaluate the effects of compounds 1-3 on the release of COX-2/PEG-2. Two target cytokines were markedly increased in LPS (Lipopolysaccharide)-stimulated RAW264.7 cells; the increase was dramatically diminished by compounds 1, 2 at 10 µMol/L and compound 3 at 25 µMol/L concentrations. The level of COX-2 was decreased by 13.06%, 14.24%, and 25.41%, respectively, by compounds 1-3, and the level of PEG-2 was decreased by 27.05%, 32.26%, and 36.41%. Ibuprofen was used as positive control and the level of COX-2/PEG-2 was decreased by 32.82% and 42.31% ( Figure 5A,B) . In general, compounds 1-3 all performed remarkable anti-inflammatory activity.
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Materials and Methods
General Experimental Procedures
FT-IR spectra were recorded on a Jasco FT-IR-4600 microscopic spectrometer (Jasco Corporation, Tokyo, Japan). UV spectra were measured on a Jasco V-550 UV/Vis spectrophotometer (Jasco Corporation, Tokyo, Japan). Melting points were determined using a Beijing Tech X-6 microscopic melting point apparatus (Beijing Tech Corporation, Beijing, China). The 1D-and 2D-NMR spectra were taken on a Bruker-AVANCEIII-010601AM-500 spectrometer (Bruker Corporation, Karlsruhe, Germany) using TMS (Tetramethylsilane) as an internal standard. ESIMS was measured on a Waters UPLC/Q-TOF mass spectrometer (Waters Corporation, Milford, MA, USA). The X-ray crystallographic data were obtained on a Rigaku X-ray diffractometer (Rigaku Corporation, Tokyo, Japan) using Cu-Kα radiation. HPLC was performed on a Waters 2695 liquid chromatograph (Waters Corporation, Milford, MA, USA) with DIKMA-Diamonsil-C18 (5 µm, 200 × 4.6 mm). Reactions were monitored by HPLC (DIKMA-Diamonsil-C18, 5 µm, 200 × 4.6 mm).
Synthesis and Purification of Compounds 1-3
All the starting reactants, solvents, and catalysts were commercially available unless otherwise stated. All solvents, except for the aqueous media, were purified by standard techniques to exclude moisture.
Synthesis of Compound 7
Magnolol (2.66 g, 0.01 mol), methyl bromoacetate (2 mL, 0.02 mol), and anhydrous potassium carbonate (Na 2 CO 3 ) (0.02 mol) in absolute methanol (50 mL) were reacted at 65 • C for 6 h. After the completion of the reaction, the mixture was filtrated while hot and the methanol was removed by vacuum distillation to give a solid residue (2.32 g, 86%, containing a mixture of 36% 7a and 46% 7b). Crystals of pure 7b could be separated manually and were used for characterization. 
Synthesis of Compounds 1 and 2
Metformin hydrochloride (6.6 g, 0.04 mol), a sodium methylate solution (5 mol/L, 8 mL), and absolute methanol (20 mL) were added to a flask and mixed at room temperature for 30 min. A methanol solution of compound 7 (4.4 g, 0.01 mol, 50 mL) was added dropwise to the flask at 65 • C, and the mixture was reacted for 12 h. After the reaction, the mixture was filtrated and the precipitate was isolated (5.33 g, 1: 47.85%, 2: 29.79%). Methanol (70 mL) and the precipitate were mixed at 60 • C for 6 h and then filtered to obtain a mixture (3.34 g, 1: 56.89%, 2: 33.58%). Then, the mixture and 70 mL DCM were mixed at 40 • C for 4 h and then filtered to obtain dichloromethane solution, which was vacuum distilled to eliminate the DCM. The white powder was washed with water to obtain compound 2 (1 g, 0.0017 mol, 97%). Then, absolute methanol solution (26 mL) of the filter cake was added into formic acid (1 mL) and then precipitated in 4 • C for 12 h. Then, the mixture was filtrated and the precipitated was isolated (1, 0.99 g, 0.0021 mol, 97%). For the anti-insulin resistance activity assay, INS-1 cells were trypsinized and seeded onto 96-well plates at a density of 1 × 10 4 cells per well. Then, we chose cells whose survival rate was between 80-90% and the cells were treated with the target compounds (50 µM for compound 1, 5 µM for compound 2, 25 µM for compound 3) in 100 µL of culture medium containing 40 mmol/L glucose in sextuplicates, and metformin was used (Sigma Inc., Shenzhen, China) as a positive control. After 48 h of treatment, the supernatant was removed, and 100 µL of sugar-free culture medium was seeded and settled for 30 min. Then, each group was seeded in 100 µL of culture medium containing 16.7 mM glucose and incubated for 1 h at 37 • C. The results were determined by Rat-Insulin ELISA kits (Nanjing Jiancheng Bioengineering Insitute, Nanjing, China).
Conclusions
In summary, we have synthesized three novel target products, 1-3, which combined two pharmacophores from berberine, magnolol, and metformin. All the products were synthesized and their anti-inflammatory activities and antidiabetic activities against INS-1 cells and RAW264.1 cells were evaluated in vitro for the first time. It is noteworthy that the crystal structures of the target product 2 and the intermediate product 7b were reported for the first time, and this method provided an inexpensive, safe, and simple way to synthesize 1,3,5-triazine derivatives. Compounds 1-3 all showed remarkable anti-inflammatory and antidiabetic effects in INS-1 cells and RAW264.1 cells compared with ibuprofen and metformin. The results demonstrated that compounds 1-3 were able to relieve the COX-2/PEG-2 destruction and stimulate an insulin secretion increment. Summarizing the obtained results in our study, we believe that compounds 1-3 have great potential as anti-inflammatory and antidiabetic agents. Moreover, various pharmacophoric groups were well-tolerated under the optimized reaction conditions; thus, they may serve as drug leads in pharmaceutical chemistry.
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